Chroma Medicine and Nvelop Therapeutics announce their merger and subsequent launch of nChroma Bio (“nChroma” or “the company”) to redefine the future of genetic medicines. nChroma brings together potent epigenetic editing plus non-viral, programmable delivery to address key limitations in the field and expand the scope of treatable diseases. Concurrent with the merger, nChroma also completed an oversubscribed $75 million financing to provide the company with additional capital to drive the lead program to meaningful clinical data and to build a robust pipeline of next generation hepatic and extrahepatic targeted therapies.
Read the full article: Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75M to Accelerate Genetic Medicines //
Source: https://www.businesswire.com/news/home/20241211660902/en/Chroma-Medicine-and-Nvelop-Therapeutics-Unite-to-Form-nChroma-Bio-Securing-75-Million-to-Accelerate-Genetic-Medicines